Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC).

被引：0
|
作者：
Yoo, Changhoon
Kim, Kyu-Pyo
Song, Ki Byung
Lee, Sang Soo
Park, Do Hyun
Song, Tae Jun
Lee, Seung Soo
Park, Jin-Hong
Hwang, Dae Wook
Lee, Jae Hoon
Shin, Sang Hyun
Shin, Eunseon
Ryoo, Baek-Yeol
Kim, Song Cheol
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea
[4] Asan Med Ctr, Dept Radiol, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[6] Asan Med Ctr, Dept Oncol, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.342
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
342
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study
    Fuyuhiko Motoi
    Sohei Satoi
    Goro Honda
    Keita Wada
    Hiroyuki Shinchi
    Ippei Matsumoto
    Masayuki Sho
    Akihiko Tsuchida
    Michiaki Unno
    Journal of Gastroenterology, 2019, 54 : 194 - 203
  • [42] Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (trial in progress)
    Bajor, David Lawrence
    Gutierrez, Martin
    Vaccaro, Gina M.
    Masood, Ashiq
    Brown-Glaberman, Ursa Abigail
    Grilley-Olson, Juneko E.
    Javle, Milind M.
    Kindler, Hedy L.
    Gbolahan, Olumide B.
    Shields, Anthony Frank
    Zalupski, Mark
    Schmitt, Michael W.
    Coveler, Andrew L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [43] A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study
    Motoi, Fuyuhiko
    Satoi, Sohei
    Honda, Goro
    Wada, Keita
    Shinchi, Hiroyuki
    Matsumoto, Ippei
    Sho, Masayuki
    Tsuchida, Akihiko
    Unno, Michiaki
    Kurata, M.
    Yanagimoto, H.
    Toyama, H.
    Nagakawa, Y.
    Maemura, K.
    Mataki, Y.
    Akahori, T.
    Kinoshita, S.
    Terashima, H.
    Horiguchi, A.
    Ohtsuka, Y.
    Nanashima, A.
    Kanemitsu, K.
    Ohigashi, H.
    Tani, M.
    Takahara, T.
    Shiomi, H.
    Endo, I.
    Suzuki, H.
    Rikiyama, T.
    Ikoma, H.
    Yasunaga, M.
    Nakamura, K.
    Egawa, S.
    Katayose, Y.
    Nakagawa, K.
    Okada, K.
    Ottomo, S.
    JOURNAL OF GASTROENTEROLOGY, 2019, 54 (02) : 194 - 203
  • [44] A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).
    Wei, Alice Chia-chi
    Ou, Fang-Shu
    Shi, Qian
    O'Reilly, Eileen Mary
    Meyerhardt, Jeffrey A.
    Wolff, Robert A.
    Kindler, Hedy L.
    Evans, Douglas B.
    Deshpande, Vikram
    Misdraji, Joseph
    Tamm, Eric P.
    Sahani, Dushyant
    Moore, Malcolm J.
    Newman, Elliot
    Merchant, Nipun B.
    Berlin, Jordan
    Goff, Laura Williams
    Pisters, Peter W. T.
    Posner, Mitchell C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Overall survival (OS) achieved with gemcitabine (G) or gemcitabine-abraxane (GA) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) who received first line modified FOLFIRINOX (m-FFX) palliative chemotherapy.
    Aung, Kyaw Lwin
    Creighton, Sean
    Fraser, Adriana
    Dodd, Anna
    Moura, Shari
    Albaba, Hamzeh
    O'Kane, Grainne M.
    Hedley, David W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
    Christelle Bouchart
    Julie Navez
    Ivan Borbath
    Karen Geboes
    Timon Vandamme
    Jean Closset
    Luigi Moretti
    Pieter Demetter
    Marianne Paesmans
    Jean-Luc Van Laethem
    BMC Cancer, 23 (1)
  • [47] A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients With Potentially Resectable Pancreatic Carcinoma
    Mark S. Talamonti
    William Small
    Mary F. Mulcahy
    Jeffrey D. Wayne
    Vikram Attaluri
    Lisa M. Colletti
    Mark M. Zalupski
    John P. Hoffman
    Gary M. Freedman
    Timothy J. Kinsella
    Philip A. Philip
    Cornelius J. McGinn
    Annals of Surgical Oncology, 2006, 13 : 150 - 158
  • [48] A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma
    Talamonti, MS
    Small, W
    Mulcahy, MF
    Wayne, JD
    Attaluri, V
    Colletti, LM
    Zalupski, MM
    Hoffman, JP
    Freedman, GM
    Kinsella, TJ
    Philip, PA
    McGinn, CJ
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 150 - 158
  • [49] A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer
    Kei Saito
    Hiroyuki Isayama
    Yoshihiro Sakamoto
    Yousuke Nakai
    Kazunaga Ishigaki
    Mariko Tanaka
    Takeyuki Watadani
    Junichi Arita
    Naminatsu Takahara
    Suguru Mizuno
    Hirofumi Kogure
    Hideaki Ijichi
    Keisuke Tateishi
    Minoru Tada
    Kiyoshi Hasegawa
    Masashi Fukayama
    Norihiro Kokudo
    Kazuhiko Koike
    Medical Oncology, 2018, 35
  • [50] A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer
    Saito, Kei
    Isayama, Hiroyuki
    Sakamoto, Yoshihiro
    Nakai, Yousuke
    Ishigaki, Kazunaga
    Tanaka, Mariko
    Watadani, Takeyuki
    Arita, Junichi
    Takahara, Naminatsu
    Mizuno, Suguru
    Kogure, Hirofumi
    Ijichi, Hideaki
    Tateishi, Keisuke
    Tada, Minoru
    Hasegawa, Kiyoshi
    Fukayama, Masashi
    Kokudo, Norihiro
    Koike, Kazuhiko
    MEDICAL ONCOLOGY, 2018, 35 (07)
12345